Product Code: ETC417031 | Publication Date: Oct 2022 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Australia Buprenorphine Market is projected to witness mixed growth rate patterns during 2025 to 2029. Growth accelerates to 0.02% in 2027, following an initial rate of 0.02%, before easing to 0.01% at the end of the period.
The buprenorphine market in Australia caters to the pharmaceutical sector, particularly in the management of opioid dependence and pain relief. Buprenorphine, a medication used for opioid replacement therapy and pain management, has seen increased usage due to its effectiveness and lower risk of abuse compared to traditional opioids. With growing awareness of opioid addiction and the need for effective treatment options, the market for buprenorphine products is expected to see continued growth, driven by pharmaceutical companies and healthcare providers.
The Australia buprenorphine market is witnessing growth due to several key drivers. Firstly, there`s a growing awareness of opioid addiction and the need for effective treatment options, driving demand for buprenorphine-based medications. Buprenorphine is a medication used in opioid replacement therapy to manage withdrawal symptoms and cravings, making it an essential tool in substance abuse treatment programs. Secondly, regulatory initiatives and public health policies aimed at reducing opioid misuse and overdose deaths are driving the adoption of buprenorphine treatment protocols. Additionally, advancements in pharmaceutical formulations, including long-acting buprenorphine implants and sublingual tablets, are expanding treatment options and improving patient compliance. Furthermore, the integration of buprenorphine treatment into primary care settings and the expansion of telemedicine services are further boosting market growth by increasing access to treatment for individuals with opioid use disorder.
The Australia buprenorphine market faces challenges such as opioid addiction treatment access and regulatory restrictions. Adapting to changes in healthcare policies and addressing concerns regarding buprenorphine diversion are ongoing challenges for pharmaceutical companies.
The buprenorphine market in Australia involves the production, distribution, and prescription of opioid medications used for pain management and opioid addiction treatment. Government regulations ensure controlled substance scheduling, prescription guidelines, and patient monitoring protocols for buprenorphine medications. Market dynamics are influenced by factors such as healthcare policies, opioid epidemic responses, pharmaceutical industry regulations, and clinical research developments in pain management and addiction treatment therapies.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Buprenorphine Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Buprenorphine Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Buprenorphine Market - Industry Life Cycle |
3.4 Australia Buprenorphine Market - Porter's Five Forces |
3.5 Australia Buprenorphine Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 Australia Buprenorphine Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Australia Buprenorphine Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Buprenorphine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and acceptance of buprenorphine as an effective treatment for opioid dependence. |
4.2.2 Rising opioid addiction rates in Australia leading to higher demand for buprenorphine. |
4.2.3 Government initiatives and policies promoting the use of buprenorphine in opioid addiction treatment. |
4.3 Market Restraints |
4.3.1 Stringent regulations and controls on the distribution and prescription of buprenorphine. |
4.3.2 Limited availability of healthcare professionals trained in buprenorphine treatment. |
4.3.3 Stigma and misconceptions associated with medication-assisted treatment for opioid addiction. |
5 Australia Buprenorphine Market Trends |
6 Australia Buprenorphine Market, By Types |
6.1 Australia Buprenorphine Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 Australia Buprenorphine Market Revenues & Volume, By Application, 2021-2031F |
6.1.3 Australia Buprenorphine Market Revenues & Volume, By Analgesic, 2021-2031F |
6.1.4 Australia Buprenorphine Market Revenues & Volume, By Opioid Antagonist, 2021-2031F |
6.2 Australia Buprenorphine Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Australia Buprenorphine Market Revenues & Volume, By Injectables, 2021-2031F |
6.2.3 Australia Buprenorphine Market Revenues & Volume, By Sublingual, 2021-2031F |
6.2.4 Australia Buprenorphine Market Revenues & Volume, By Transdermal Patches, 2021-2031F |
6.3 Australia Buprenorphine Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Australia Buprenorphine Market Revenues & Volume, By Hospital Pharmacies, 2021-2031F |
6.3.3 Australia Buprenorphine Market Revenues & Volume, By Retail Pharmacies, 2021-2031F |
6.3.4 Australia Buprenorphine Market Revenues & Volume, By Online Pharmacies, 2021-2031F |
7 Australia Buprenorphine Market Import-Export Trade Statistics |
7.1 Australia Buprenorphine Market Export to Major Countries |
7.2 Australia Buprenorphine Market Imports from Major Countries |
8 Australia Buprenorphine Market Key Performance Indicators |
8.1 Patient retention rate in buprenorphine treatment programs. |
8.2 Number of healthcare facilities offering buprenorphine treatment. |
8.3 Rate of successful outcomes in buprenorphine treatment programs. |
9 Australia Buprenorphine Market - Opportunity Assessment |
9.1 Australia Buprenorphine Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 Australia Buprenorphine Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Australia Buprenorphine Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Buprenorphine Market - Competitive Landscape |
10.1 Australia Buprenorphine Market Revenue Share, By Companies, 2024 |
10.2 Australia Buprenorphine Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |